U.S. Professional Services Stock News

NasdaqGS:UNIT
NasdaqGS:UNITTelecom

Is Uniti’s 8.625% 2032 Note Offering Reshaping the Investment Case for Uniti Group (UNIT)?

In January 2026, Uniti Group Inc. issued new fixed-income securities, including US$500,000,000 of 8.625% senior notes and US$1 billion of 8.625% senior unsecured notes due 2032 under Regulation S and Rule 144A, with attached guarantees. The completion of these large, guaranteed senior unsecured note offerings materially reshapes Uniti Group’s capital structure and future interest obligations. We’ll now examine how Uniti Group’s sizable 8.625% senior unsecured notes due 2032 may influence...
NasdaqGS:TRMK
NasdaqGS:TRMKBanks

Trustmark’s Record Earnings And Buyback Plan Underline Shareholder Return Focus

Trustmark (NasdaqGS:TRMK) has reported record full-year earnings, highlighting strong performance across core banking, mortgage banking, and wealth management. The company has raised its quarterly dividend, signaling confidence in its balance sheet and ongoing cash generation. Trustmark also approved a new $100 million stock repurchase program, adding another lever for returning capital to shareholders. At a recent share price of $42.32, Trustmark comes into this news with solid longer term...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Does Strong Financials And Rare-Disease Partnerships Change The Bull Case For Catalyst Pharmaceuticals (CPRX)?

In recent days, Catalyst Pharmaceuticals has been highlighted for strong earnings and revenue growth, solid profitability, and a debt-free balance sheet, earning it a spot on an “Affordable Growth” screen. At the same time, upbeat analyst views and collaborations with BioMarin Pharmaceutical and Endo Ventures have reinforced Catalyst’s rare-disease focus as a key differentiator in the biotechnology space. We’ll now examine how Catalyst’s combination of robust financial health and...
NYSE:LAZ
NYSE:LAZCapital Markets

Lazard (LAZ) Margin Compression To 7.6% Tests Bullish Earnings Growth Narratives

Lazard (LAZ) has capped FY 2025 with fourth quarter revenue of US$906.7 million, basic EPS of US$0.50 and net income excluding extra items of US$49.9 million, setting a clear marker for how the year wrapped up. The firm has seen quarterly revenue move from US$811.4 million in Q4 2024 to US$906.7 million in Q4 2025, while Q4 EPS shifted from US$0.89 to US$0.50 over the same stretch, giving investors a mixed read on top line scale and per share profitability as they weigh what softer margins...
NYSE:MPLX
NYSE:MPLXOil and Gas

Is MPLX (MPLX) Still Attractively Priced After Its Recent Strong Share Price Run?

If you are wondering whether MPLX is still reasonably priced after its strong run, this article will help you make sense of where the current share price sits against different views of value. With the stock at US$56.24 and returns of 1.2% over 7 days, 4.8% over 30 days, 4.4% year to date and 13.9% over 1 year, many investors are asking whether the recent performance reflects growth potential or a shift in perceived risk. Over the past few months, MPLX has attracted attention as investors...
NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Gold Royalty (GROY) Valuation After Borborema Royalty Deal And Record Preliminary Revenue

Gold Royalty (GROY) has been in focus after reporting preliminary revenue of US$4,501,000 for the quarter and US$15,610,000 for 2025, alongside acquiring a net smelter royalty on Brazil’s Borborema gold mine. See our latest analysis for Gold Royalty. At a share price of US$4.65, Gold Royalty has seen a 26.02% 90 day share price return and a very large 263.28% 1 year total shareholder return. This suggests recent momentum that contrasts with the 1 day and 7 day pullback, as the market weighs...